2seventy bio Inc Ordinary Shares TSVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients
-
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million
-
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
-
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
-
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy
-
Correction to 2seventy to Sell R&D Pipeline Article
-
2seventy to Sell R&D Pipeline to Regeneron, Focus on Abecma
-
Bristol Myers Gets Positive CHMP Opinion for Earlier Abecma Use
Trading Information
- Previous Close Price
- €170.00
- Day Range
- €97.26–97.26
- 52-Week Range
- €97.26–347.00
- Bid/Ask
- €90.00 / €77.55
- Market Cap
- €8.53 Bil
- Volume/Avg
- 113 / 178
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 425
- Website
- https://www.2seventybio.com
Comparables
Valuation
|
Metric
|
TSVT
|
FULC
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.20 |
Price/Book Value | 1.17 | 0.91 | 3.53 |
Price/Sales | 2.76 | 3.08 | 4.01 |
Price/Cash Flow | — | — | 16.42 |
Price/Earnings
TSVT
FULC
EXEL
Financial Strength
|
Metric
|
TSVT
|
FULC
|
EXEL
|
|---|---|---|---|
Quick Ratio | 4.66 | 21.84 | 4.05 |
Current Ratio | 4.76 | 22.07 | 4.27 |
Interest Coverage | — | — | — |
Quick Ratio
TSVT
FULC
EXEL
Profitability
|
Metric
|
TSVT
|
FULC
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −25.06% | −1.76% | 14.82% |
Return on Equity (Normalized) | −53.74% | −1.91% | 19.05% |
Return on Invested Capital (Normalized) | −30.13% | −1.83% | 14.99% |
Return on Assets
TSVT
FULC
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zwdjrkgtl | Tvqs | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ynpcxlcr | Nwlmqpr | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ftlbcsfx | Syzytcy | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bfszhxxv | Bqtmsdy | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Ftrhbwsl | Fbtj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jcbdtvzvz | Klwv | $28.0 Bil | |||
| Moderna Inc
MRNA
| Yykgvdsw | Vlcq | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Vbktslw | Xzy | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mkklvmp | Wvmqg | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fgcncmszd | Lllvfpg | $12.6 Bil |
United States